Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 11, 2017, Pages 3141-3148

  Hunt, Gillian M ^a,b   Dokubo, E Kainne ^c   Takuva, Simbarashe ^a,b   de Oliveira, Tulio ^d,e   Ledwaba, Johanna ^a   Dube, Nomathemba ^a   Moodley, Pravi ^f   Sabatier, Jennifer ^c   Deyde, Varough ^c   Morris, Lynn ^a,b   Raizes, Elliot ^c  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

^e UNIVERSITY OF KWAZULU NATAL   (South Africa)

^f UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS DIDANOSINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GENOTYPE; HEALTH CARE FACILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SOUTH AFRICA; VIRUS LOAD; ADOLESCENT; BLOOD; DRUG EFFECT; GENETICS; HEALTH CARE DELIVERY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; MUTATION; OUTPATIENT DEPARTMENT; SENTINEL SURVEILLANCE; TREATMENT FAILURE; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AMBULATORY CARE FACILITIES; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; DELIVERY OF HEALTH CARE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; SENTINEL SURVEILLANCE; SOUTH AFRICA; TREATMENT FAILURE; VIRAL LOAD; YOUNG ADULT;

EID: 85044859230     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx252     Document Type: Article

References (30)

1. UNAIDS. Global AIDS Update 2016. http://www. unaids. org/en/resources/ documents/2016/Global-AIDS-update-2016
2. World Health Organization. HIV Drug Resistance Surveillance Guidance 2015 Update. http://www. who. int/hiv/pub/drugresistance/hiv-drug-resist ance-2015-update/en/
3. World Health Organization. Concept Note: Surveillance of HIV Drug Resistance in Adults Receiving ART (Acquired HIV Drug Resistance). 2014. http:// apps. who. int/iris/bitstream/10665/112801/1/9789241507073_eng. pdf
4. Shisana O, Rehle T, Simbayi LC et al. South African National HIV Prevalence, Incidence and Behaviour Survey, 2012. Human Sciences Research Council, 2014. http://www. hsrc. ac. za/uploads/pageContent/4565/SABSSM%20IV%20 LEO%20final. pdf
5. Joint Review of HIV, TB and PMTCT Programmes in South Africa-April 2014. http://www. hst. org. za/publications/joint-review-hiv-tb-and-pmtctprogrammes-south-africa-april-2014
6. The 2012 National Antenatal Sentinel HIV and Herpes Simplex Type-2 Prevalence Survey in South Africa. https://www. health-e. org. za/wp-content/ uploads/2014/05/ASHIVHerp_Report2014_22May2014. pdf
7. 2013/14 Annual Report Vote 7. Pietermaritzburg: KwaZulu-Natal Department of Health, 2015. http://www. kznhealth. gov. za
8. Parboosing R, Naidoo A, Gordon M et al. Resistance to antiretroviral drugs in newly diagnosed, young treatment-naive HIV-positive pregnantwomen in the province of KwaZulu-Natal, South Africa. JMedVirol 2011; 83: 1508-13
9. Manasa J, Katzenstein D, Cassol S et al. for the Southern Africa Treatment And Resistance Network (SATuRN). Primary drug resistance in South Africa: data from 10 years of surveys. AIDS Res HumRetroviruses 2012; 28: 558-65
10. Hunt GM, Ledwaba J, Basson AE et al. Surveillance of transmitted HIV-1 drug resistance in the Gauteng and KwaZula-Natal regions of South Africa from 2005-2009. Clin Infect Dis 2011; 54 Suppl 4: S334-8
11. ParikhUM, Kiepiela P, Ganesh S et al. Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009). PLoS One 2013; 8: e59787
12. Manasa J, Danaviah S, Lessells R et al. Increasing HIV-1 drug resistance between 2010 and 2012 in adults participating in population-based HIV surveillance in rural KwaZulu-Natal, South Africa. AIDS Res Hum Retroviruses 2016; 32: 763-9
13. Marconi VC, Sunpath H, Lu Z et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008; 46: 1589-97
14. Manasa J, Lessells RJ, Skingsley A et al. High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa. PLoS One 2013; 8: e72152
15. Kiepiela P, Manasa J, MoosaM-Y et al. HIV drug resistance patterns at the epicentre of the HIV-1 epidemic in Kwazulu-Natal, South Africa 2003-2013. JAIDSClinRes 2014; 5: 299
16. Pillay V, Ledwaba J, Hunt G et al. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 2008; 13 Suppl 2: 101-7
17. Libin P, Beheydt G, Deforche K et al. RegaDB: community-driven data management and analysis for infectious diseases. Bioinformatics 2013; 29: 1477-80
18. The South African Antiretroviral Treatment Guidelines 2010. http://apps. who. int/medicinedocs/documents/s19153en/s19153en. pdf
19. The South African Antiretroviral Treatment Guidelines 2013. http://www. kznhealth. gov. za/medicine/2013_art_guidelines. pdf
20. World Health Organization. WHO Definitions of Clinical, Immunological and Virological Failure for the Decision to Switch ART Regimens, 2013. http:// www. who. int/hiv/pub/guidelines/arv2013/art/WHO_CG_table_7. 15. pdf
21. Sunpath H, Wu B, Gordon M et al. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovircontaining first-line regimen. AIDS 2012; 26: 1679-84
22. Van Zyl GU, Liu TF, ClaassenMet al. Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first-and second-line antiretroviral treatment regimens. PLoS One 2013; 8: e67188
23. Skhosana L, Steegen K, BronzeMet al. High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa. PLoS One 2015; 10: e0118145
24. The TenoRes Study Group. Global epidemiology of drug resistance after failure ofWHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis 2016; 16: 565-75
25. Brenner BG, OliveiraM, Doualla-Bell F et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006; 20: F9-13
26. Xu HT, Martinez-Cajas JL, Ntemgwa ML et al. Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance. Retrovirology 2009; 6: 14
27. Parikh UM, Zelina S, Sluis-Cremer N et al. Molecular mechanisms of bidirectional antagonismbetween K65R and thymidine analog mutations in HIV-1. reverse transcriptase. AIDS 2007; 21: 1405-14
28. McMahon JH, Elliott JH, Bertagnolio S et al. Viral suppression after 12months of antiretroviral therapy in low-and middle-income countries: a systematic review. Bull World Health Organ 2013; 91: 377-85E
29. Lecher S, Ellenberger D, Kim AA et al. Scale-up of HIV viral load monitoring-seven sub-Saharan African countries. MMWR Morb Mortal Wkly Rep 2015; 64: 1287-90
30. Boender TS, Sigaloff KC, McMahon JH et al. Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low-andmiddle-income countries: a systematic review and meta-analysis. Clin Infect Dis 2015; 61: 1453-61